Results
1
-
10
of
50
<
1
2
3
4
5
>
Raynaud JP; Cousse H; Martin PM.
Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon.
,
The Journal of steroid biochemistry and molecular biology
[PubMed: 12477490]
Pope LE; Marcelletti JF; Katz LR; Katz DH.
Anti-herpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug.
,
Journal of lipid research
[PubMed: 8906594]
Mei L; Lu Z; Zhang W; Wu Z; Zhang X; Wang Y; Luo Y; Li C; Jia Y.
Bioconjugated nanoparticles for attachment and penetration into pathogenic bacteria.
,
Biomaterials
[PubMed: 24090838]
[DOI: 10.1016/j.biomaterials.2013.09]
Watanabe K; Inoue H; Teshigawara T; Kimura T.
?-gel prepared in sodium methyl stearoyl taurate/behenyl alcohol/water system-characterization of structural changes with water concentration.
,
Journal of oleo science
[Docosanol (Erazaban), dermal use].
,
Journal de pharmacie de Belgique
Docosanol: new drug. Herpes labialis: barely more effective than an excipient.
,
Prescrire international
Abdel-Haq N; Chearskul P; Al-Tatari H; Asmar B.
New antiviral agents.
,
Indian journal of pediatrics
Elish D; Singh F; Weinberg JM.
Therapeutic options for herpes labialis, II: Topical agents.
,
Cutis
Docherty JJ; Smith JS; Fu MM; Stoner T; Booth T.
Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice.
,
Antiviral research
Sacks SL.
Efficacy of docosanol.
,
Journal of the American Academy of Dermatology
<
1
2
3
4
5
>